The national COPD screening programme in China: rationale and design
Jieping Lei(Chinese Academy of Medical Sciences & Peking Union Medical College), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Fen Dong(China-Japan Friendship Hospital), Cunbo Jia(Chinese Academy of Medical Sciences & Peking Union Medical College), Ting Yang(University Medical Center Groningen), Baicun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Ke Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoxia Ren(Johns Hopkins University), Yong Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Pan(China-Japan Friendship Hospital), Wei Li(Chinese Academy of Sciences), Hongtao Niu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 10
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.7k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k